Chongqing Key Laboratory for Pharmaceutical Metabolism Research, Chongqing Pharmacodynamic Evaluation Engineering Technology Research Center, College of Pharmacy, Chongqing Medical University, 400016, Chongqing, P. R. China.
Nat Commun. 2022 Nov 1;13(1):6528. doi: 10.1038/s41467-022-34248-y.
Considering that intravascular reactive oxygen species (ROS) and inflammation are two characteristic features of the atherosclerotic microenvironment, developing an appropriate strategy to treat atherosclerosis by synergistically regulating ROS and inflammation has attracted widespread attention. Herein, a special molecule, zoledronic acid, containing imidazole and bisphosphonate groups, was selected for the first time to assist the assembly of cerium ions and produce functionalized ceria-zoledronic acid nanocomposites (CZ NCs). It not only serves as a new carrier for different kinds of drugs (e.g. probucol, PB) but also exerts an efficient multienzyme activity to achieve collaborative therapy. More importantly, platelet membrane-coated biomimetic nanoplatform (PCZ@PB NCs) specifically accumulate at inflammatory atherosclerotic lesions, synergistically regulate ROS levels and inflammation, and efficiently inhibit foam cell formation. This novel assembly method can also be applied in the treatment of many other diseases associated with oxidative stress and inflammation.
考虑到血管内活性氧(ROS)和炎症是动脉粥样硬化微环境的两个特征,因此开发一种通过协同调节 ROS 和炎症来治疗动脉粥样硬化的合适策略引起了广泛关注。在此,首次选择了一种特殊分子唑来膦酸,它含有咪唑和双膦酸盐基团,以协助组装铈离子并产生功能化的氧化铈-唑来膦酸纳米复合材料(CZ NCs)。它不仅可以作为不同种类药物(如普罗布考,PB)的新型载体,还具有高效的多酶活性以实现协同治疗。更重要的是,血小板膜包覆的仿生纳米平台(PCZ@PB NCs)特异性地在炎症性动脉粥样硬化病变处聚集,协同调节 ROS 水平和炎症,并有效抑制泡沫细胞形成。这种新的组装方法也可以应用于治疗许多其他与氧化应激和炎症相关的疾病。